Oxular IE Limited
- Address
- Spaces 1st Floor Building Two, The Green Airport Central
Sponsor Overview
Specializations
Retinal Disease and Macular Edema
Oxular IE Limited focuses on diabetic macular edema, a vision-threatening complication of diabetes mellitus that affects the retina and central macula. Its clinical research is centered on treatment options for retinal fluid accumulation and visual impairment associated with this condition.
- Diabetic macular edema
- Retinal edema
- Macular pathology
The sponsor’s research activity in this area is directed toward ophthalmic intervention for preserving central vision in people with diabetic eye disease.
Ophthalmic Drug Delivery
The sponsor has an active interest in suprachoroidal administration, reflecting a therapeutic focus on targeted delivery within the eye. This route is being explored for its relevance to localized treatment of retinal disorders.
- Suprachoroidal delivery
- Intraocular therapy
- Targeted ocular treatment
Clinical evaluation in this domain supports development of approaches intended to address disease activity within posterior segment eye structures.
Corticosteroid-Based Eye Therapy
Research activity also includes comparison with established intravitreal corticosteroid treatment for diabetic macular edema. This places the sponsor within therapeutic work involving anti-inflammatory management of retinal swelling and fluid leakage.
- Intravitreal corticosteroids
- Ocular anti-inflammatory therapy
- Retinal fluid control
The therapeutic interest lies in ophthalmic options used to manage macular thickening and associated visual compromise.
Visual Function in Diabetes-Related Eye Disease
Oxular IE Limited’s clinical focus remains within the domain of diabetic eye disease, where treatment goals are closely tied to maintaining visual acuity and central retinal function. The sponsor’s funded research aligns with interventions for patients experiencing sight loss from retinal complications of diabetes.
- Visual acuity
- Central vision
- Diabetic eye disease
This area of interest reflects a narrow ophthalmic therapeutic scope concentrated on preserving retinal function in metabolic disease-related ocular pathology.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Suprachoroidal Dexamethasone Acetate (OXU-001) Versus Intravitreal Dexamethasone Implant in Diabetic Macular Edema |  Hungary Spain | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 11 sites across their trial portfolio.
Therapeutic Focus
- 1.Eye Diseases1 trial138 other sponsors
Partnered Research Centres
11 centres- Address
- Avenida de la Arruzafa, 9, 14012 Córdoba
- Address
- Dos De Maig 301, 08025 Barcelona
- Address
- Calle De Pizarro 15 Bajo, 46004 Valencia
- Address
- Calle Villarroel 170, 08036 Barcelona
- Address
- Carrer Pedro I Pons 1, 08195 Sant Cugat del Vallès
- Address
- Avenida De Cordoba Sn, 28041 Madrid
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Oxular IE Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.